1. United States Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Bruker Corporation

Bruker Corporation

49.50
EUR
-2.40
(-4.63%)
-0.37EPS
7.87BMarket Cap
Nov 04Next Earn
Bruker Corporation
DUS:BKD
(Dusseldorf Stock Exchange)

Recent

price

49.50

P/E

ratio

- -

div

yld

0.64%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
7.94
9.99
10.79
11.05
10.78
9.65
9.98
11.17
12.14
13.35
12.96
15.97
17.03
20.25
22.59
22.64
23.01
Revenue per Share
0.58
0.56
0.47
0.48
0.34
0.6
0.95
0.5
1.15
1.27
1.03
1.83
2
2.92
0.76
-0.15
-0.7
Basic EPS, GAAP
0.76
0.16
0.36
0.57
0.48
1.16
0.58
0.7
1.22
0.9
1.53
1.26
0.98
1.66
0.91
0.09
0.62
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.16
0.16
0.16
0.16
0.16
0.16
0.2
0.2
0.2
0.22
0.36
Dividend per Share
3.18
3.75
4.24
5.05
4.54
4.39
4.29
4.65
5.73
5.88
6.32
7.1
7.58
9.49
11.74
16.15
15.63
Book Value per Share
1.76
2.32
2.84
3.66
3.29
3.15
3.04
3.04
2.57
2.47
2.71
3.44
2.62
3.2
-4.21
0.06
0.55
Tangible Book Value per Share
164
165
166
167
168
168
161
158
156
155
153
151
149
146
149
152
152
Basic Weighted Avg Shares
1,305
1,652
1,791
1,839
1,809
1,624
1,611
1,766
1,896
2,073
1,988
2,418
2,531
2,965
3,366
3,437
3,500
Sales/Revenue/Turnover
12.38
9.95
10.19
9.28
7.46
9.86
12.88
13.53
14.63
14.73
13.45
17.64
18.27
16.5
11.26
6.87
7.6
Operating Margin (%)
36
53
59
61
60
53
54
64
65
76
81
89
89
115
184
220
230
Depreciation Expense
95
92
78
80
57
102
154
79
180
197
158
277
297
427
113
-9
-71
Net Income, GAAP
35.51
35.4
43.46
34.35
41.16
18.05
13.01
59.4
26.03
29.39
28.52
28.71
28.12
21.63
44.18
133.18
- -
Effective Tax Rate (%)
7.31
5.59
4.33
4.35
3.13
6.26
9.53
4.45
9.48
9.51
7.94
11.46
11.72
14.41
3.36
-0.25
-2.03
Profit Margin (%)
220
438
628
783
784
677
751
834
705
1,151
1,133
1,533
1,199
962
772
933
1,020
Working Capital
87
219
336
354
354
265
392
416
323
860
889
1,264
1,235
1,235
2,181
1,991
1,815
LT Debt
527
625
710
850
772
733
693
734
928
938
974
1,085
1,132
1,413
1,815
2,510
2,436
Total Equity
13.72
10.67
8.42
8.3
5.16
10.81
14.64
7.72
15.44
13.24
9.13
12.91
12.28
12.57
3.96
-0.51
- -
Return on Invested Capital (%)
14.1
10.85
8.6
7.74
5.29
10.25
15.61
7.38
15.53
13.45
8.88
13
12.55
16.89
4.06
-0.67
- -
Return on Capital (%)
20.26
16.11
11.67
10.32
7.03
13.62
21.75
11.13
22.16
21.87
16.9
27.28
27.16
34.3
7.16
-1.06
-5.11
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
52
8
10
LT Borrowings
1,853
1,663
1,815
LT Finance Leases
139
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
152
152
152
Market Capitalization
7,240
5,418
8,990

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,213
2,104
2,225
Cash, Cash Equivalents & STI
299
133
223
Accounts Receivable, Net
545
543
546
Inventories
1,095
1,122
1,120
Total Current Liabilities
1,279
1,355
1,205
Payables & Accruals
441
269
200
ST Debt
52
8
10
Deferred Revenue
441
480
445

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.91%
21.45%
38.29%
Free Cash Flow
-2.97%
-21.82%
-89.78%
Net Income, GAAP
6.63%
-10.89%
-107.6%
Sales/Revenue/Turnover
8.05%
11.82%
2.08%
Total Cash Common Dividend
- -
-2.84%
-37.09%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
722
801
864
980
3,366
2025
801
797
861
977
3,437
2026
823
839
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.05
0.27
0.09
0.76
2025
0.11
0.05
-0.41
0.1
-0.15
2026
0.02
-0.41
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.05
0.05
0.05
0.2
2025
0.05
0.05
- -
0.12
0.22
2026
0.12
0.12
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bruker Corporation (Nasdaq: BRKR) develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at molecular, cellular, and microscopic levels. The company offers a broad portfolio of products including nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) spectrometers; mass spectrometry systems; X-ray diffraction, scattering, and microscope analyzers; infrared, near-infrared, and Raman spectroscopy instruments; fluorescence and electron microscopy solutions; preclinical imaging systems; elemental analyzers; surface plasmon resonance systems; microbiology and clinical diagnostic tools such as ClinMASS and ClinDART kits; CBRNE detectors; semiconductor metrology equipment; and laboratory automation, data management, and test & measurement solutions. These products support applications in life science molecular research, pharmaceuticals, biotechnology, materials science, microscopy and nanoanalysis, industrial quality control, preclinical imaging, clinical phenomics and proteomics, and clinical microbiology. Founded in 1960 and headquartered in Billerica, Massachusetts, Bruker operates globally with over 11,000 employees across more than 90 locations on all continents, serving academic, governmental, pharmaceutical, biotechnology, and industrial customers. In April 2025, Bruker announced a majority investment in RECIPE Chemicals + Instruments GmbH, a Munich-based provider of clinical diagnostic assays, enhancing its small molecule diagnostics capabilities through integration of RECIPE's ClinMASS kits for EVOQ liquid chromatography triple-quadrupole mass spectrometers and upcoming high-throughput ClinDART kits for chromatography-free workflows on EVOQ-DART systems. Earlier, in 2024, the company acquired Dynamic Biosensors GmbH to strengthen its biosensor portfolio for molecular interaction analysis, complementing high-performance surface plasmon resonance systems like SPR #64 'Triceratops' for pharmaceutical and biotechnology drug discovery. Bruker also secured approximately $10 million in federally funded NMR system orders in October 2025 from institutions including the New York Structural Biology Center, University of Delaware, and Northwestern University, while initiating a major cost savings program targeting $100-120 million in annual reductions by fiscal 2026 amid market pressures.

Company News

Company News APIChatGPT

  • businesswire.com

    Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast

  • gurufocus.com

    Is Bruker Corp (BRKR) a Bargain After 3.1% Drop? GF Value Says Undervalued

  • zacks.com

    Bruker Gains 66.3% in a Year: What's Driving the Rally?

  • gurufocus.com

    Bruker Corp (BRKR) Shares Fall 5.3% -- GF Value Says Still Overvalued

  • businesswire.com

    Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

  • zacks.com

    Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term

  • defenseworld.net

    Bruker (NASDAQ:BRKR) Sets New 1-Year High – Should You Buy?

  • investorplace.com

    Neuralink Stock: How to Invest Before the IPO

  • gurufocus.com

    Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

  • businesswire.com

    Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

  • marketbeat.com

    Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound

  • seekingalpha.com

    Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • businesswire.com

    Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

  • seekingalpha.com

    Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • seekingalpha.com

    Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  • gurufocus.com

    Bruker Corporation to Present at Upcoming Investor Conferences

  • businesswire.com

    Bruker Corporation to Present at Upcoming Investor Conferences

  • gurufocus.com

    BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

  • businesswire.com

    BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

  • zacks.com

    Why Is Bruker (BRKR) Up 12.5% Since Last Earnings Report?